Illinois College Jacksonville, Illinois
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Redalyc.MAIN FUNGAL PARTNERS and DIFFERENT LEVELS OF
Lankesteriana International Journal on Orchidology ISSN: 1409-3871 [email protected] Universidad de Costa Rica Costa Rica Suárez, Juan Pablo; Kottke, Ingrid MAIN FUNGAL PARTNERS AND DIFFERENT LEVELS OF SPECIFICITY OF ORCHID MYCORRHIZAE IN THE TROPICAL MOUNTAIN FORESTS OF ECUADOR Lankesteriana International Journal on Orchidology, vol. 16, núm. 2, 2016 Universidad de Costa Rica Cartago, Costa Rica Available in: http://www.redalyc.org/articulo.oa?id=44347813012 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative LANKESTERIANA 16(2): 00–00. 2016. doi: http://dx.doi.org/10.15517/lank.v15i2.00000 MAIN FUNGAL PARTNERS AND DIFFERENT LEVELS OF SPECIFICITY OF ORCHID MYCORRHIZAE IN THE TROPICAL MOUNTAIN FORESTS OF ECUADOR JUAN PABLO SUÁREZ1,3 & INGRID KOTTKE2 1 Departamento de Ciencias Naturales, Universidad Técnica Particular de Loja, San Cayetano Alto s/n C.P. 11 01 608, Loja, Ecuador* 2 Plant Evolutionary Ecology, Institute of Evolution and Ecology, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 1, 72076 Tübingen, Germany; retired 3 Corresponding author: [email protected] ABSTRACT. Orchids are a main component of the diversity of vascular plants in Ecuador with approximately 4000 species representing about 5.3% of the orchid species described worldwide. More than a third of these species are endemics. As orchids, in contrast to other plants, depend on mycorrhizal fungi already for seed germination and early seedling establishment, availability of appropriate fungi may strongly influence distribution of orchid populations. -
Phylogenetic Relationships of Rhizoctonia Fungi Within the Cantharellales
fungal biology 120 (2016) 603e619 journal homepage: www.elsevier.com/locate/funbio Phylogenetic relationships of Rhizoctonia fungi within the Cantharellales Dolores GONZALEZa,*, Marianela RODRIGUEZ-CARRESb, Teun BOEKHOUTc, Joost STALPERSc, Eiko E. KURAMAEd, Andreia K. NAKATANIe, Rytas VILGALYSf, Marc A. CUBETAb aInstituto de Ecologıa, A.C., Red de Biodiversidad y Sistematica, Carretera Antigua a Coatepec No. 351, El Haya, 91070 Xalapa, Veracruz, Mexico bDepartment of Plant Pathology, North Carolina State University, Center for Integrated Fungal Research, Campus Box 7251, Raleigh, NC 27695, USA cCBS Fungal Biodiversity Centre, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands dDepartment of Microbial Ecology, Netherlands Institute of Ecology (NIOO/KNAW), Droevendaalsesteeg 10, 6708 PB Wageningen, The Netherlands eUNESP, Faculdade de Ci^encias Agronomicas,^ CP 237, 18603-970 Botucatu, SP, Brazil fDepartment of Biology, Duke University, Durham, NC 27708, USA article info abstract Article history: Phylogenetic relationships of Rhizoctonia fungi within the order Cantharellales were studied Received 2 January 2015 using sequence data from portions of the ribosomal DNA cluster regions ITS-LSU, rpb2, tef1, Received in revised form and atp6 for 50 taxa, and public sequence data from the rpb2 locus for 165 taxa. Data sets 1 January 2016 were analysed individually and combined using Maximum Parsimony, Maximum Likeli- Accepted 19 January 2016 hood, and Bayesian Phylogenetic Inference methods. All analyses supported the mono- Available online 29 January 2016 phyly of the family Ceratobasidiaceae, which comprises the genera Ceratobasidium and Corresponding Editor: Thanatephorus. Multi-locus analysis revealed 10 well-supported monophyletic groups that Joseph W. Spatafora were consistent with previous separation into anastomosis groups based on hyphal fusion criteria. -
Annexes to the EMA Annual Report 2009
Annual report 2009 Annexes The main body of this annual report is available on the website of the European Medicines Agency (EMA) at: http://www.ema.europa.eu/htms/general/direct/ar.htm 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. Contents Annex 1 Members of the Management Board..................................................... 3 Annex 2 Members of the Committee for Medicinal Products for Human Use .......... 5 Annex 3 Members of the Committee for Medicinal Products for Veterinary Use ....... 8 Annex 4 Members of the Committee on Orphan Medicinal Products .................... 10 Annex 5 Members of the Committee on Herbal Medicinal Products ..................... 12 Annex 6 Members of the Paediatric Committee................................................ 14 Annex 7 National competent authority partners ............................................... 16 Annex 8 Budget summaries 2008–2009 ......................................................... 27 Annex 9 European Medicines Agency Establishment Plan .................................. 28 Annex 10 CHMP opinions in 2009 on medicinal products for human use .............. 29 Annex 11 CVMP opinions in 2009 on medicinal products for veterinary use.......... 53 Annex 12 COMP opinions in 2009 on designation of orphan medicinal products -
Regional-Scale In-Depth Analysis of Soil Fungal Diversity Reveals Strong Ph and Plant Species Effects in Northern Europe
fmicb-11-01953 September 9, 2020 Time: 11:41 # 1 ORIGINAL RESEARCH published: 04 September 2020 doi: 10.3389/fmicb.2020.01953 Regional-Scale In-Depth Analysis of Soil Fungal Diversity Reveals Strong pH and Plant Species Effects in Northern Europe Leho Tedersoo1*, Sten Anslan1,2, Mohammad Bahram1,3, Rein Drenkhan4, Karin Pritsch5, Franz Buegger5, Allar Padari4, Niloufar Hagh-Doust1, Vladimir Mikryukov6, Daniyal Gohar1, Rasekh Amiri1, Indrek Hiiesalu1, Reimo Lutter4, Raul Rosenvald1, Edited by: Elisabeth Rähn4, Kalev Adamson4, Tiia Drenkhan4,7, Hardi Tullus4, Katrin Jürimaa4, Saskia Bindschedler, Ivar Sibul4, Eveli Otsing1, Sergei Põlme1, Marek Metslaid4, Kaire Loit8, Ahto Agan1, Université de Neuchâtel, Switzerland Rasmus Puusepp1, Inge Varik1, Urmas Kõljalg1,9 and Kessy Abarenkov9 Reviewed by: 1 2 Tesfaye Wubet, Institute of Ecology and Earth Sciences, University of Tartu, Tartu, Estonia, Zoological Institute, Technische Universität 3 Helmholtz Centre for Environmental Braunschweig, Brunswick, Germany, Department of Ecology, Swedish University of Agricultural Sciences, Uppsala, 4 5 Research (UFZ), Germany Sweden, Institute of Forestry and Rural Engineering, Estonian University of Life Sciences, Tartu, Estonia, Helmholtz 6 Christina Hazard, Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany, Chair of Ecole Centrale de Lyon, France Forest Management Planning and Wood Processing Technologies, Institute of Plant and Animal Ecology, Ural Branch, Russian Academy of Sciences, Yekaterinburg, Russia, 7 Forest Health and Biodiversity, Natural Resources Institute Finland *Correspondence: (Luke), Helsinki, Finland, 8 Chair of Plant Health, Estonian University of Life Sciences, Tartu, Estonia, 9 Natural History Leho Tedersoo Museum and Botanical Garden, University of Tartu, Tartu, Estonia [email protected] Specialty section: Soil microbiome has a pivotal role in ecosystem functioning, yet little is known about This article was submitted to its build-up from local to regional scales. -
Understanding and Managing Rhizoctonia Solani In
UNDERSTANDING AND MANAGING RHIZOCTONIA SOLANI IN SUGARBEET A Thesis Submitted to the Graduate Faculty Of the North Dakota State University of Agriculture and Applied Science By Afsana Noor In Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Major Department: Plant Pathology May 2013 Fargo, North Dakota North Dakota State University Graduate School Title UNDERSTANDING AND MANAGING RHIZOCTONIA SOLANI IN SUGARBEET By Afsana Noor The Supervisory Committee certifies that this disquisition complies with North Dakota State University’s regulations and meets the accepted standards for the degree of MASTER OF SCIENCE SUPERVISORY COMMITTEE: Dr. Mohamed Khan Chair Dr. Luis del Rio Dr. Marisol Berti Dr. Melvin Bolton Approved: Dr. Jack B. Rasmussen 10/04/13 Date Department Chair ABSTRACT Rhizoctonia crown and root rot of sugarbeet (Beta vulgaris L.) caused by Rhizoctonia solani Kühn is one of the most important production problems in Minnesota and North Dakota. Greenhouse studies were conducted to determine the efficacy of azoxystrobin to control R. solani at seed, cotyledonary, 2-leaf and 4-leaf stages of sugarbeet; compatibility, safety, and efficacy of mixing azoxystrobin with starter fertilizers to control R. solani; and the effect of placement of azoxystrobin in control of R. solani. Results demonstrated that azoxystrobin provided effective control applied in-furrow or band applications before infection at all sugarbeet growth stages evaluated; mixtures of azoxystrobin and starter fertilizers were compatible, safe, and provided control of R. solani; and azoxystrobin provided effective control against R. solani when placed in contact over the sugarbeet root or into soil close to the roots. -
Myocardial Metabolism in Heart Failure: Purinergic Signalling and Other
Accepted Manuscript Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts Andreas L. Birkenfeld, Jens Jordan, Markus Dworak, Tobias Merkel, Geoffrey Burnstock PII: S0163-7258(18)30153-0 DOI: doi:10.1016/j.pharmthera.2018.08.015 Reference: JPT 7270 To appear in: Pharmacology and Therapeutics Please cite this article as: Andreas L. Birkenfeld, Jens Jordan, Markus Dworak, Tobias Merkel, Geoffrey Burnstock , Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts. Jpt (2018), doi:10.1016/j.pharmthera.2018.08.015 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts Andreas L. Birkenfeld MD1,2,3,4, Jens Jordan MD5, Markus Dworak PhD6, Tobias Merkel PhD6 and Geoffrey Burnstock PhD7,8. Affiliations 1Medical Clinic III, Universitätsklinikum "Carl Gustav Carus", Technische Universität Dresden, Dresden, Germany 2Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine, Dresden, German Center for Diabetes Research -
Adenosine A1 Receptor Antagonists in Clinical Research and Development Berthold Hocher1,2
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector mini review http://www.kidney-international.org & 2010 International Society of Nephrology Adenosine A1 receptor antagonists in clinical research and development Berthold Hocher1,2 1Institute of Nutritional Science, University of Potsdam, Potsdam, Germany and 2Center for Cardiovascular Research/Department of Pharmacology and Toxicology, Charite´, Campus Mitte, Berlin, Germany Selective adenosine A1 receptor antagonists targeting renal Various lines of evidence implicate impaired renal function as microcirculation are novel pharmacologic agents that are a risk factor in patients with congestive heart failure (CHF). currently under development for the treatment of acute Conventional diuretics may aggravate renal dysfunction and heart failure as well as for chronic heart failure. Despite can result in neurohumoral activation and activation of the several studies showing improvement of renal function TGF mechanism in the kidney.1 Impaired kidney function and/or increased diuresis with adenosine A1 antagonists, might not just be a risk factor, but is also currently observed particularly in chronic heart failure, these findings were as having a role—and thus potentially as target—in disease not confirmed in a large phase III trial in acute heart failure progression of heart failure patients.1 Evolving new ther- patients. However, lessons can be learned from these and apeutic strategies that enhance renal function include other studies, and there might still be a potential role for administration of B-type natriuretic peptide, adenosine the clinical use of adenosine A1 antagonists. and vasopressin antagonists, and ultrafiltration methods. We review the role of adenosine A1 receptors in the Prospective studies are needed to evaluate whether these new regulation of renal function, and emerging data regarding renal-enhancing strategies will improve patient outcome in the safety and efficacy of A1 adenosine receptor antagonists CHF. -
Heart Failure Guidelines
; ; ; † § ** ; ; † † * ; ; † † ; ; ¶ † ; * † * ; . 2013;128:e240–e327. † ; DOI: 10.1161/CIR.0b013e31829e8776 †‡ Circulation * †† * ; Tamara Horwich, MD, FACC Tamara ; ‖ ; Barbara Riegel, DNSc, RN, FAHA ; Barbara Riegel, ; Patrick E. McBride, MD, MPH, FACC ; Patrick † ; Wayne C. Levy, MD, FACC C. Levy, Wayne ; # † † ; Emily J. Tsai, MD, FACC ; Emily J. ; Biykem Bozkurt, MD, PhD, FACC, FAHA Bozkurt, MD, PhD, FACC, ; Biykem ; Gregg C. Fonarow, MD, FACC, FAHA MD, FACC, C. Fonarow, ; Gregg † † † * * * e240 ; Lynne W. Stevenson, MD, FACC Stevenson, W. ; Lynne ; Judith E. Mitchell, MD, FACC, FAHA ; Judith E. Mitchell, MD, FACC, † † ; Maryl R. Johnson, MD, FACC, FAHA ; Maryl R. Johnson, MD, FACC, * † * ; Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA FACP, MD, MPH, MBA, Jr, ; Donald E. Casey, † * WRITING COMMITTEE MEMBERS Bruce L. Wilkoff, MD, FACC, FHRS MD, FACC, Wilkoff, Bruce L. Journal of the American College of Cardiology. American College of the Journal Management of Heart Failure Clyde W. Yancy, MD, MSc, FACC, FAHA, Chair FAHA, MD, MSc, FACC, Yancy, W. Clyde ACCF/AHA Practice Guideline ACCF/AHA International Society for Heart and Lung Transplantation International Society for Heart and Lung 2013 ACCF/AHA Guideline for the Guideline for ACCF/AHA 2013 W.H. Wilson Tang, MD, FACC Tang, Wilson W.H. Flora Sam, MD, FACC, FAHA Flora Sam, MD, FACC, Heart Association Task Force on Practice Guidelines Force Task Association Heart Edward K. Kasper, MD, FACC, FAHA MD, FACC, K. Kasper, Edward James L. Januzzi, MD, FACC John J.V. McMurray, MD, FACC McMurray, John J.V. Stephen A. Geraci, MD, FACC, FAHA, FCCP FAHA, A. Geraci, MD, FACC, Stephen . 2013;128:e240-e327.) is available at http://circ.ahajournals.org is available Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation Association of Cardiovascular American by the Endorsed Pamela N. -
Ceratobasidium Cereale D
CA LIF ORNIA D EPA RTM EN T OF FOOD & AGRICULTURE California Pest Rating Proposal for Ceratobasidium cereale D. Murray & L.L. Burpee 1984 Yellow patch of turfgrass/sharp eye spot of cereals Current Pest Rating: Z Proposed Pest Rating: C Kingdom: Fungi; Phylum: Basidiomycota Class: Agaricomycetes; Subclass: Agaricomycetidae Order: Ceratobasidiales; Family: Ceratobasidiaceae Comment Period: 3/24/2020 through 5/8/2020 Initiating Event: On 1/29/2020, a regulatory sample for nursery cleanliness from a commercial sod farm was submitted by an agricultural inspector in San Joaquin County to the CDFA plant diagnostics center. The turf was grown from a 90% tall dwarf fescue and 10% bluegrass seed mix. On February 10, 2020, CDFA plant pathologist Suzanne Rooney-Latham detected Ceratobasidium cereale (syn. Rhizoctonia cerealis) in culture from yellow leaf blades. This fungus causes yellow patch disease on turfgrass. Due to previous reports of this pathogen from University of California farm advisors, it was assigned a temporary Z rating. The risk to California from Ceratobasidium cereale is assessed herein and a permanent rating is proposed. History & Status: Background: The name Ceratobasidium cereale was proposed by Murray and Burpee in 1984 after they were able to induce otherwise sterile isolates that had been classified as Corticium gramineum or Rhizoctonia cerealis to form the basidia (sexual state) on agar. Their work resulted in the name Corticium gramineum being reduced to a nomen dubium (doubtful name). However, because the production of basidia has not been observed under field conditions, many still use the name Rhizoctonia cerealis to CA LIF ORNIA D EPA RTM EN T OF FOOD & AGRICULTURE describe a pathogen that does not produce spores and is composed only of sterile hyphae and sclerotia. -
WO 2011/089216 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK). -
MK-7418 Prot. No. 301-302 PROTECT 2. Synopsis
MK-7418 Prot. No. 301-302 PROTECT 2. Synopsis MERCK RESEARCH CLINICAL STUDY REPORT LABORATORIES SYNOPSIS MK-7418 rolofylline, IV Congestive Heart Failure PROTOCOL TITLE/NO.: A Multicenter, Randomized, Double-Blind, Placebo- #301-302 Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects with Acute Heart Failure Syndrome and Renal Impairment who are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy. PROTECTION OF HUMAN SUBJECTS: This study was conducted in conformance with applicable country or local requirements regarding ethical committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of human subjects participating in biomedical research. For study audit information see [16.1.8]. INVESTIGATOR(S)/STUDY CENTER(S): Multicenter 239 sites Worldwide, 18 countries [16.1.3.1; 16.1.4.1] PUBLICATION(S): PRIMARY THERAPY PERIOD: 02May2007 to 23JAN2009. CLINICAL III Day 60 Follow-Up completed 23MAR2009; Day 180 Follow-up PHASE: completed 30JUL2009. DURATION OF TREATMENT: All patients were treated with active drug or exact match placebo given as a 4-hour intravenous infusion for up to 3 days or until discharge, whichever occurred first. OBJECTIVE(S): The objectives of this study were to evaluate the effect of rolofylline in addition to intravenous (IV) loop diuretic therapy on heart failure signs and symptoms, persistent renal dysfunction, morbidity and mortality, and safety in subjects hospitalized with acute heart failure syndrome (AHFS), volume overload, and renal impairment, and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with rolofylline and placebo. -
In Vivo Pharmacological Profiling in Xenopus Embryos Defines a Subset of A1 Adenosine Receptor-Selective Antagonists with Potent
Aus dem Biomedizinischen Zentrum Institut für Chirurgische Forschung (Walter-Brendel-Zentrum für experimentelle Medizin) der Ludwig-Maximilians-Universität München Kommissarischer Vorstand: Prof. Dr. med. dent. Reinhard Hickel In vivo pharmacological profiling in Xenopus embryos defines a subset of A1 adenosine receptor-selective antagonists with potent anti-angiogenic activities Dissertation zum Erwerb des Doktorgrades der Naturwissenschaften an der Medizinischen Fakultät der Ludwig-Maximilians-Universität München vorgelegt von Mazhar Gull aus Pakistan 2016 Mit Genehmigung der Medizinischen Fakultät der Universität München Erstgutachter: Prof. Dr. phil. André W. Brändli Zweitgutachter: Prof. Dr. Ralph A.W. Rupp Dekan: Prof. Dr. med. dent. Reinhard Hickel Tag der mündlichen Prüfung: 07.07.2017 “You never change things by fighting the existing reality. To change something, build a new model that makes the existing model obsolete.” R. Buckminster Fuller Table of Contents: Table of figures ........................................................................................ IX Table of tables ......................................................................................... XI Abstract ................................................................................................ XIII Zusammenfassung ................................................................................. XIV Introduction .............................................................................................. 1 A chemical genetic screen in Xenopus